Pixium Vision - Back to basics as Second Sight deal is called off
Pixium announced on 3 April that it had been notified by Second Sight of its unilateral decision to terminate the January 2021 memorandum of understanding (MOU) relating to the proposed business combination of both entities. Although Pixium is seeking legal avenues to gain compensation from Second Sight in excess of the €1m termination fee that had already been offered, we are not entirely disappointed the business combination plan fell through, because Pixium’s shareholders will now benefit from the full future economics of the Prima system. Pixium remains focused and committed to advancing Prima, which is continuing in a pivotal EU study (PRIMAvera), and the company is examining short- and longer-term financing options, including methods to access US markets.Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.